lncTAC

lncRNA is one of the hottest and most cutting-edge subfields in current biomedical basic research. By exploring lncRNA, solutions can be provided for a series of unmet clinical needs in disease treatment. Under the leadership of Professor Song Xu, a pioneer in the field of lncRNA research, lncTAC has become the first innovative enterprise in China to focus on lncRNA drug development. lncTAC possesses the world's leading lncRNA-mediated Targeting Chimera technology (lncTAC®) and, together with UNAST®, forms a unique technical platform capable of developing innovative nucleic acid drugs targeting a series of traditionally undruggable targets.